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Cyclosporin Avolume is a key issue in cellular pathophysiology. Mitochondrial volume and shape
changes can occur following regulated ﬁssion–fusion events, which are modulated by a complex network of
cytosolic and mitochondrial proteins; and through regulation of ion transport across the inner membrane. In
this review we will cover mitochondrial volume homeostasis that depends on (i) monovalent cation transport
across the inner membrane, a regulated process that couples electrophoretic K+ inﬂux on K+ channels to K+
extrusion through the K+–H+ exchanger; (ii) the permeability transition, a loss of inner membrane
permeability that may be instrumental in triggering cell death. Speciﬁc emphasis will be placed on molecular
advances on the nature of the transport protein(s) involved, and/or on diseases that depend on mitochondrial
volume dysregulation.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Chemiosmotic energy conservation demands both a “low perme-
ability to protons and to anions and cations generally” (4th postulate)
and “substrate-speciﬁc exchange-diffusion carrier systems that
permit the effective reversible trans-membrane exchange of anions
against OH− ions and of cations against H+ ions” (3rd postulate) [1,2].
After a long debate, a general consensus has been reached on the
following points: (i) the inner membrane has an intrinsically low
permeability to charged species; (ii) inner membrane channels exist,
which mediate cation uptake across the inner membrane and whose
conductance is tightly controlled; (iii) cation uptake is counter-
balanced by cation efﬂux via pathways that are designed to prevent
excessive osmotic swelling (K+–H+ and Na+–H+ exchangers) and
calciﬁcation of mitochondria (Ca2+ efﬂux systems); and (iv) the inner
membrane permeability can increase because of a “permeability
transition” [3] due to opening of the permeability transition pore
(PTP), a regulated high conductance channel [4]. Mitochondrial
volume and shape changes can also occur following regulated
ﬁssion–fusion events, which are modulated by a complex network
of cytosolic and mitochondrial proteins [5]. In this short review we
will only cover mitochondrial volume homeostasis that depends on KCD, N,N′-dicyclohexylcarbodii-
ion pore; ROS, reactive oxygen
phy; WHS, Wolf–Hirschhorn
ll rights reserved.+ transport across the inner membrane, a regulated process that
couples electrophoretic K+ inﬂux on K+ channels to K+ extrusion
through the K+–H+ exchanger (KHE); and the permeability transi-
tion. Speciﬁc emphasis will be placed on recent advances on the
molecular nature of the transport protein(s) involved, and/or on
diseases that depend on mitochondrial volume deregulation through
these systems.
An increase of mitochondrial volume can occur via two distinct
mechanisms, which were clearly identiﬁed as early as in 1965 [6]. The
ﬁrst type of swelling (the high-energy swelling of Azzone and Azzi)
occurs in energized mitochondria (i.e., in mitochondria that maintain a
low passive permeability to protons, and therefore also maintain a
transmembrane electrical potential difference,which is themaindriving
force for K+ accumulation). Swelling occurs when electrophoretic K+
inﬂux rate (via leaks and/or opening of K+ channels) exceeds the rate of
K+ release through theKHE. K+uptake is compensatedbyH+extrusion,
driving in turn the accumulation of Pi so that the accumulated species is
eventually K-Pi, which is responsible for the osmotic swelling of the
matrix. The second type of swelling (the low-energy swelling of Azzone
and Azzi) instead occurs in deenergizedmitochondria (i.e. inmitochon-
dria that are depolarized because of opening of the PTP, which causes a
generalized increase of permeability to solutes with molecular masses
up to about 1500 Da). In this case no ion gradients can be maintained,
and swelling occurs because of the osmotic pressure exerted by non
diffusible matrix proteins and macromolecular complexes. PTP opening
requiresmatrix Ca2+ and Pi, and is regulated by the H+ electrochemical
gradient in the sense that depolarization favors PTP opening while an
acidic matrix pH inhibits it [7].
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expansion and unfolding of the cristae, which in turn increases the
fraction of intermembrane cytochrome c [8]; if matrix expansion
exceeds the viscoelastic resistance of the outer membrane, rupture of
the latter causes release of intermembrane proteins, including
cytochrome c and apoptosis-inducing factor. Apoptosis or necrosis
may follow, depending on whether ATP levels remain high enough to
allow caspase 9 activation [9,10].
2. K+ channels
The inner mitochondrial membrane displays low but measur-
able electrophoretic permeability to K+, with an estimated
conductance of 0.11 nmol K+×mg protein−1×min−1×mV−1
[11], which is comparable to the basal H+ conductance of
0.2 nmol×mg protein−1×min−1×mV−1 [12]. The K+ (and Na+)
conductance can be increased dramatically after depletion of
divalent cations with EDTA and A23187 [13,14] through channel
(s) that are inhibited by ruthenium red [15]. The nature of these
channels is still unknown, but it appears possible that divalent
cation depletion allows monovalent cation ﬂux through the
mitochondrial Ca2+ uniporter [15], as shown by patch-clamp
experiments for Na+ [16]. A variety of K+ channels have been
described in the inner mitochondrial membrane.
KATP channels, selective K+ channels inhibited by ATP, were ﬁrst
identiﬁed in liver mitochondria by patch-clamp experiments [17] and
then extensively characterized by pharmacology, particularly in
relation to their role in cardioprotection [18]. A Shaker-type Kv1.3
channel has been identiﬁed in lymphocytes [19] and macrophages
[20]. Its interactionwith Bax, which behaves like K+ channel-blocking
toxins, is an important step in the process of mitochondrial apoptosis
in lymphocytes [21]. Ca2+-activated Big Conductance K+ (BK) channels
were originally described in a human glioma cell line, as a cationic
conductance that opens when matrix Ca2+ increases [22]. Cytopro-
tective BK channels are also present in brain [23–25], skeletal muscle
[26] and heart [27] mitochondria, and their expression may be
regulated by oxygen availability [28]. Finally, the mitochondrial
expression of two-pore domain TASK-3 channels has been recently
described in both normal and transformed human cells [29].
3. K+–H+ exchanger
As mentioned above, electrophoretic K+ entry must be compen-
sated by K+ efﬂux. The relative activity of these systems regulates
mitochondrial K+ and volume homeostasis, and contributes to
regulation of matrix pH. While the existence of the KHE has been
demonstrated beyond reasonable doubt by a number of experimental
approaches (see [4] for review) its molecular nature has remained an
open question.
3.1. Molecular nature of K+–H+ exchanger
Based on the discovery that N,N′-dicyclohexylcarbodiimide
(DCCD) irreversibly inhibits the KHE under very selective conditions,
Martin et al. used [14C]DCCD labeling of mitochondria to identify a
82 kDa protein as the putative KHE [30]. The puriﬁed protein
reconstituted into lipid vesicles catalyzed DCCD- and Mg2+-sensitive
electroneutral K+(Na+)–H+ exchange [31]. As of today the identity of
the 82 kDa species is not known.
While characterizing a collection of yeast genes putatively
encoding mitochondrial cation transporters, Nowikovsky et al. [32]
identiﬁed Mdm38p (Yol027cp) as essential for mitochondrial K+–H+
exchange activity and for respiratory growth of yeast cells. Passive
swelling experiments with isolated yeast mitochondria in K+ acetate
(a sensitive method that allows detection of electroneutral K+–H+
exchange activity, see [4] for review) and direct K+–H+ exchangeassays in yeast submitochondrial particles demonstrated that
Mdm38p/Yol027cp is essential for growth and for mitochondrial
K+–H+ exchange, which was totally lacking in mdm38 knock-out
mutants [32,33]. These results are compelling evidence that
Mdm38p/Yol027cp is an essential component of the mitochondrial
KHE [32,33].
Strong support for this hypothesis came from the ﬁnding that
nigericin, which catalyzes electroneutral K+–H+ exchange, restored
aerobic growth of Mdm38p/Yol027cp-null yeast strains and reverted
mitochondrial swelling in situ [34]. Reversion to normal mitochon-
drial K+ homeostasis and growth features was also achieved by
expression of the Mdm38p yeast homologues Ypr125wp/Mrs7p and
of the human homolog of Mdm38p/Yol027cp, LETM1. Since all these
proteins are functionally conserved from yeast to man, and are
essential components of the KHE, Mdm38p was renamed Mkh1p.
Mkh1p family proteins including human LETM1 bear only one
transmembrane domain, suggesting that they may not constitute the
KHE itself (at least as a monomer) but rather an essential component
that allows the exchange activity to take place. Indeed, biochemical
data indicate that these proteins are part of a higher molecular weight
complex [35,36] suggesting that the KHE might consist of discrete
subunits.
3.2. K+–H+ exchanger and Wolf–Hirschhorn Syndrome
TheWolf–Hirschhorn Syndrome (WHS, MIM 194190) is a complex
disease involving the central nervous system [37,38] caused by partial,
heterozygous deletion of the terminal portion of the short arm of one
chromosome 4 involving the 4p16.3 region [39,40]. A critical region of
165 kb including several genes has been deﬁned (WHSCR-1) that
causes the clinical hallmarks of the disease, i.e. severe growth and
mental retardation, hypotonia, midline fusion defects and typical
facial dysmorphism [41,42]. A subset of cases of WHS is also
characterized by seizures, which start during the ﬁrst year of life
and are a frequent cause of death [43]. Interestingly, the LETM1 gene
has been localized less than 80 kb distal to the WHSCR-1 region. It is
invariably deleted in WHS patients with seizures and is preserved in
those without epilepsy [44] irrespective of the WHSCR-1 deletion.
These ﬁndings render the LETM1 haploinsufﬁciency a potential
causative event for seizures associated with WHS and possibly for
other forms of epilepsy. Given the key role of LETM1 in mitochondrial
K+ homeostasis, it may be predicted that reduced activity of the KHE
is followed by osmotic matrix swelling, outer membrane rupture,
cytochrome c release and impaired ATP production. In fact, over-
expression of Mkh1p resulted in mitochondrial matrix contraction,
while Mkh1 protein depletion in wild-type cells caused matrix
swelling [34,36]; and, like in the yeast model, mitochondrial swelling
and fragmentation of Mkh1p-depleted cells could be rescued by
proper amounts of nigericin [35], ﬁndings that further underscore the
role of the mitochondrial K+ cycle in pathophysiological swelling–
contraction events of the organelles. If our working hypothesis on the
role of LETM1 in WHS is correct, impaired mitochondrial ATP
production following mitochondrial swelling may affect the neurons'
ability to maintain the plasma membrane potential, and possibly
increase excitability to the threshold required to trigger seizures, a
hypothesis that has not been tested so far. Fibroblastoid cells from one
WHS patient showed a detectable decrease in LETM1 protein content,
but there was no obvious phenotypic effect on mitochondria. Only
stronger reduction in LETM1 expression caused mitochondrial
changes and ﬁnally cell death [35]. Yet it is well possible that in
other types of cells, e.g. neurons, WHS patients have LETM1 protein
contents below a threshold sufﬁcient for maintaining mitochondrial
cation homeostasis. Thus, the basis for cell dysfunction inWHSmay be
lowered K+–H+ exchange activity, which could be treated with
pharmacological agents. To summarize, molecular and physiological
studies on yeast and human cell cultures underscore the prominent
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homeostasis, and genetic studies on WHS patients identify the
deletion of the human KHE gene LETM1 as most likely responsible
for seizures associated with the disease. Understanding the patho-
physiology of LETM1 deﬁciency in vivo may thus lead to important
advances toward the therapy of WHS and possibly of other forms of
CNS diseases with seizures, which are often linked to mitochondrial
defects [45] and may also involve the PTP [46].
4. Permeability transition pore
The PTP is a high-conductance, Ca2+-activated channel modulated
by a variety of pathophysiological effectors [47–49] (see [50,51] for
recent reviews). Despite intensive studies, the molecular nature of the
PTP remains unsolved, and popular candidates such as the adenine
nucleotide translocator and VDAC did not stand testing in mitochon-
dria where the relevant protein(s) had been ablated by genetic
methods [52–54] (see [55] for review). The onlymolecular regulator of
the PTP identiﬁed so far is cyclophilin (CyP)-D, a matrix peptidyl–
prolyl-cis–trans-isomerase whose enzymatic activity can be inhibited
by cyclosporin (Cs)A [56], with parallel desensitization of the PTP to
opening [57–59]. At variance from immunosuppression, desensitiza-
tion of the PTP byCsAdoesnot involve calcineurin, and can be achieved
with CyP inhibitors devoid of immunosuppressive activity [60–62].
Since the discovery of its desensitizing properties on the PTP, CsA
has become the standard tool to test the role of the PTP in disease
models. Its widespread utilization is largely responsible for our
increased understanding of the role of the PTP in pathophysiology of
diseases (see [50] for an extensive review). A key advance is the recent
demonstration that acute administration of a single intravenous bolus
of 2.5 mg CsA×kg−1 body weight immediately before percutaneous
coronary intervention decreased the infarcted area by about 40% in
treated vs untreated patients, a ﬁnding that holds great promise for
the treatment of coronary infarction [63].
The role of CyP-D as an endogenous regulator of the PTP has
been unequivocally demonstrated in mitochondria from mice with
genetic inactivation of the Ppif gene, which encodes CyP-D in the
mouse [64–67]. Mitochondria from Ppif−/− individuals display a
higher Ca2+ threshold for PTP opening which matches that of CsA-Fig. 1. Mitochondrial volume homeostasis mediated by K+ transport and the PTP. The sc
homeostasis. Kc, potassium channels; ETC, electron transfer chain; Mkh1, essential mitocho
transition pore. For explanation see text.treated mitochondria from wild-type, strain-matched individuals.
The Ppif−/− mice are strikingly resistant to ischemia–reperfusion
injury of the heart [64,66] and brain [67], and to experimental
autoimmune encephalomyelitis [68].
Through the use of CsA the unexpected mitochondrial pathoge-
nesis of collagen VI myopathies, diseases due to mutations of the
collagen VI genes, has recently been established. Myopathic mice with
genetic inactivation of the Col6a1 gene (which completely lack the
collagen VI protein) [69] undergo muscle ﬁber death due to increased
opening of the PTP [70]. In the ﬁrst example of a genetic muscle
disease that could be cured with a drug, CsA rescued the mice from
ﬁber cell death through a demonstrably mitochondrial effect [70].
These promising results were extended to cultures from patients with
collagen VI muscular dystrophies, where both CsA and Debio 025 (a
non immunosuppressive CyP inhibitor) repaired the mitochondrial
functional defect [71]; and to 4 patients with Ullrich Congenital
Muscular Dystrophy and 1 patient with Bethlem Myopathy, who all
underwent amelioration of the mitochondrial phenotype and apop-
totic rate, with increased muscle regeneration, after short-term
treatment with CsA [72]. Recent studies on cultured myoblasts from
patients with Ullrich Congenital Muscular Dystrophy suggest that the
PTP voltage threshold is shifted toward the resting potential by
chronic Ca2+ overload of the sarcoplasmic reticulum–mitochondrial
functional complex, which in turn makes pore opening more likely to
occur [73].
Recent results suggest that inappropriate PTP opening may also
play a role in other forms of muscular dystrophy. Indeed, crossing
Ppif−/− mice with dystrophic mice lacking delta-sarcoglycan mark-
edly decreased the disease in both skeletal muscle and heart; and
crossing with mice bearing the deletion of Lama2 (which encodes the
alpha-2 chain of laminin-2) cured the premature lethality and other
indices of this dystrophic disease model [74]. Results are also available
on treatment ofmdxmice (a model of DuchenneMuscular Dystrophy)
with the CyP inhibitor Debio 025, a derivative of CsA that maintains
the PTP desensitizing properties but is devoid of immunosuppressive
activity [71]. High dose (50 mg/kg/d) treatment with Debio 025
yielded only partial protection from ﬁbrosis and minimal reversal of
central nucleation [74], and similar results have been obtained with
lower doses given orally [75]. The latter authors also performedheme summarizes the role of K+ ﬂuxes and PTP opening in mitochondrial volume
ndrial KHE factor; Δψ, mitochondrial membrane potential difference; PTP, permeability
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mechanical stress was improved and relaxation time was reduced by
Debio 025 indicating improved Ca2+ handling, an effect that was not
seen with CsA [75]. Based on these results, it appears likely that PTP
opening plays a role in DuchenneMuscular Dystrophy as well, but that
either the effects of CyP-D inhibition on the PTP are less effective (e.g.
because of the high Ca2+ levels) or because additional pathways, such
as activation of the ubiquitin–proteasome pathway, are the determi-
nant factors in this disease [76].
5. K+ ﬂuxes and the permeability transition
Since the PTP is modulated by themembrane voltage [7], opening of
K+ channels should favor PTP opening. Consistent with this prediction,
Scorrano et al. have demonstrated that treatment of isolated mitochon-
dria with valinomycin in K+-based media caused PTP opening, with
increasing fractions of mitochondria opening their pores as the
depolarizing K+ current increased [77]. In these experiments enough
nigericin (which catalyzes electroneutral K+–H+ exchange) was added
to prevent K+ accumulation. Since valinomycin forms a charged
complex with K+ allowing the electrophoretic transport of K+ across
the inner membrane, this experimental setup should be equivalent to
opening of selective inner membrane K+ channels [77].
Rather than causing increased damage through the PTP, however,
opening of mitochondrial KATP channels has instead been reported to
have a cardioprotective role (reviewed in [18]) through an inhibitory
effect on the PTP [78–80]. According to Facundo et al. the protective
effect is due to a decreased production of ROS [79], while Garlid and
coworkers contend that opening of K+ channels (or addition of
valinomycin) causes increased production of ROS, followed by
activation of PKCɛ which would eventually lead to PTP inhibition
[80]. The basis for these discrepancies is not immediately obvious, but
the intriguing possibility exists that increased K+ conductance
through endogenous channels may affect the probability of opening
depending on the status of the PTP at the onset of the K+ current, in
particular the presence of a permissive matrix load of Ca2+ and
phosphate [81], and on the complex balance of all factors (both
inducing and inhibiting) which modulate the PTP open time [4].
In this context the recent work of Szabó et al. on mitochondrial
Kv1.3 channels and Bax-induced apoptosis is extremely relevant [21].
This work demonstrated that in lymphocytes Bax physically interacts
with and inhibits Kv1.3 channels causing hyperpolarization and then
overproduction of ROS, which eventually causes PTP opening, stable
depolarization, cytochrome c release and apoptosis [21]. Thus, the
consequences of K+ channel opening or closing on ROS production,
PTP opening and cell survival may also depend on the cell type and on
additional factors, such as Bax for Kv1.3 channels. While it is perhaps
too early to draw general conclusions on the mechanistic links
between K+ ﬂuxes and PTP regulation, however, a general consensus
is emerging that the PTP is the target for cytoprotection downstream
of K+. channels.
6. Mitochondrial swelling and autophagy
Changes of mitochondrial volume may strongly modulate mito-
chondrial physiology. Moreover, osmotic swelling is one of the funda-
mental features of pathological states of mitochondria, which results
in the activation of downstream cascades, most notably life-or-death
decisions that also include the switch between necrosis and apoptosis
[9]. An emerging hypothesis is that swelling may trigger autophagy, a
process through which aging or damaged organelles are degraded via
the lysosomal pathway, a process also called “mitophagy” [34,82]. This
phenomenon has been observed following both opening of the PTP
[82] and lack of the KHE [34], with nigericin reverting both swelling
and mitophagy in the latter case [34]. These observations suggests
that swelling itself rather than the underlying cause (dysregulation ofK+ homeostasis or opening of the PTP) triggers mitophagy, possibly as
the result of exposure of the inner membrane following outer
membrane rupture. It cannot be excluded, however, that lack of the
KHE may contribute to PTP opening because of the ensuing matrix
swelling, which causes dilution of pore inhibitory factors like Mg2+
and adenine nucleotides.
7. Summary
Fig. 1 summarizes the topics discussed in the review, and
highlights the consequences of deregulation of K+ ﬂuxes and PTP
opening on mitochondrial volume homeostasis. Under physiological
conditions (scheme 1) owing to the low passive permeability of the
inner membrane (and to the closed state of the PTP) H+ pumping by
the electron transfer chain (ETC) creates a proton electrochemical
gradient, which is largely in the form of a membrane potential
difference (Δψ). Inﬂux of K+ via K+ channels (Kc) causes a transient
depolarization which is compensated by increased electron ﬂux and
increased H+ pumping. The buildup of a K+ gradient (and matrix
swelling) is prevented by operation of the KHE (Mkh1) (the matching
Pi ﬂuxes driven by oscillation of the ΔpH are omitted for clarity, see [4]
for review). In the absence of the Mkh1 protein (or for a lower activity
of the exchange process), K+ inﬂux is not compensated and thematrix
expands (scheme 2), yet the permeability barrier of the inner
membrane is maintained, the membrane potential is lowered
(probably by increased H+ leaks) and swelling can be reverted by
the artiﬁcial KHE nigericin. PTP opening could occur because of the
lowered Δψ, Mg2+ dilution and alkalinization (scheme 3), leading to
complete collapse of the Δψ, ion/solute equilibration and secondary
impairment of respiration due to release of pyridine nucleotides and
cytochrome c, and to substrate depletion. PTP opening could also
occur in KHE-competent mitochondria because of Ca2+/Pi overload
and increased ROS balance. Swollenmitochondria undergomitophagy
and/or contribute to cell death.
8. Conclusions
Over 50 years after its formulation, the chemiosmotic theory of
energy conservation maintains all its vitality, and provides the
framework that allows to understand mitochondrial bioenergetics in
the cell. In his summary of the basic postulates, Mitchell stated that “It
will now be useful to summarise the basis of the chemiosmotic
coupling hypothesis in the form of four essential postulates; for, these
postulates can be used, on the one hand, for the further development
of the theory of chemiosmotic coupling, and on the other hand, as the
target for critical experiments designed to show that the chemiosmo-
tic hypothesis may be untenable” [1]. We are conﬁdent that the
continuing work on the molecular deﬁnition of mitochondrial cation
transport and of the PTP will contribute to our understanding of
mitochondrial volume homeostasis; and add to the enormous amount
of critical experiments that show that the chemiosmotic hypothesis is
not untenable.
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Note added in proof
A manuscript relevant to the relationship between activity of the
KHEandPTPproposedherewas recently published. A simulation based
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between the mitochondrial membrane potential difference (Δ ψ) and
theΔpH is affected by the ratio of the rate constants of K+uniport (i.e.,
the sum of the rate constants for all K+ channels) and of KHE, with a
sharp decrease of Δ ψ and increase of Δ pH as the ratio increases, as it
occurs when the activity of KHE decreases [Dzbek and Korzerniewski
(2008) J Biol Chem in press 10.1074/jbc.M802404200]. The decrease of
Dy after switching off Mkh1p has actually beenmeasured [34], and the
combination of depolarization and matrix alkalinization is a powerful
trigger for PTP opening [4].
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